{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:06:28Z","timestamp":1760267188128},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1097\/mjt.0b013e318250f83d","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T07:35:49Z","timestamp":1347003349000},"page":"523-534","source":"Crossref","is-referenced-by-count":15,"title":["Management of Gouty Arthritis in Patients With Chronic Kidney Disease"],"prefix":"10.1097","volume":"21","author":[{"given":"Abdul A.","family":"Abdellatif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naser","family":"Elkhalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210202","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007 -2008.","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":". Prevalence of contraindications and prescription of pharmacologic therapies for gout.","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"R3-16-20210202","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/RHU.0b013e318232615b","article-title":"Impact of deficits in gout care on hospitalizations.","volume":"17","author":"Nitichaikulvatana","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"R4-16-20210202","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":". Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R5-16-20210202","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00005792-196012000-00001","article-title":"The kidney in gout.","volume":"39","author":"Talbott","year":"1960","journal-title":"Medicine (Baltimore)"},{"key":"R6-16-20210202","first-page":"526","article-title":"Uric acid: a novel mediator and marker of risk in chronic kidney disease Curr Opin Nephrol Hypertens.","volume":"18","author":"Feig","year":"2009","journal-title":""},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":". EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"R10-16-20210202","first-page":"ix26","article-title":"How does early chronic kidney disease progress A background paper prepared for the UK Consensus Conference on early chronic kidney disease.","volume":"22","author":"Metcalfe","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R11-16-20210202","first-page":"145","article-title":"Hyperuricemic nephropathies.","volume":"81suppl","author":"Steele","year":"1999","journal-title":"Nephron"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","article-title":". Risk factors for end-stage renal disease: 25-year follow-up.","volume":"169","author":"Hsu","year":"2009","journal-title":"Arch Intern Med"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2188\/jea.10.403","article-title":". Does hyperuricemia affect mortality A prospective cohort study of Japanese male workers.","volume":"10","author":"Tomita","year":"2000","journal-title":"J Epidemiol"},{"key":"R14-16-20210202","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.ajkd.2006.08.019","article-title":". J-shaped mortality relationship for uric acid in CKD.","volume":"48","author":"Suliman","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R15-16-20210202","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","article-title":". Uric acid and long-term outcomes in CKD.","volume":"53","author":"Madero","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R17-16-20210202","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":". Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R18-16-20210202","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","article-title":". Gout: an independent risk factor for all-cause and cardiovascular mortality.","volume":"49","author":"Kuo","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","article-title":". Gout and the risk of acute myocardial infarction.","volume":"54","author":"Krishnan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2009.122770","article-title":". Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study.","volume":"69","author":"De Vera","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"14351","DOI":"10.1073\/pnas.1001072107","article-title":". Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.","volume":"107","author":"Hershfield","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-16-20210202","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/kep306","article-title":"The modern management of gout.","volume":"49","author":"Rider","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R24-16-20210202","first-page":"1487","article-title":"Drug dosing adjustments in patients with chronic kidney disease.","volume":"75","author":"Munar","year":"2007","journal-title":"Am Fam Physician"},{"key":"R25-16-20210202","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1681\/ASN.V115974","article-title":"Renal transplant-associated hyperuricemia and gout.","volume":"11","author":"Clive","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R26-16-20210202","first-page":"919","article-title":"Managing gout: how is it different in patients with chronic kidney disease Cleve Clin J Med.","volume":"77","author":"El-Zawawy","year":"2010","journal-title":""},{"key":"R27-16-20210202","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice: gout.","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl J Med"},{"key":"R29-16-20210202","first-page":"48","article-title":"Treatment of acute gouty arthritis in patients with chronic kidney disease.","volume":"14","author":"Dykeman-Sharpe","year":"2004","journal-title":"CANNT J"},{"key":"R31-16-20210202","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.rhu.0000135555.83088.a2","article-title":"Dosing of antirheumatic drugs in renal disease and dialysis.","volume":"10","author":"Swarup","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"R32-16-20210202","first-page":"1566","article-title":"Treatment of acute gout in hospitalized patients.","volume":"34","author":"Petersel","year":"2007","journal-title":"J Rheumatol"},{"key":"R33-16-20210202","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008.","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"R34-16-20210202","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/RHU.0b013e318156d977","article-title":"Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.","volume":"13","author":"Justiniano","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"R35-16-20210202","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","article-title":"Colchicine myotoxicity: case reports and literature review.","volume":"24","author":"Wilbur","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R36-16-20210202","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":". Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"R37-16-20210202","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":". Comparison of oral prednisoloneparacetamol and oral indomethacinparacetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial.","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"key":"R38-16-20210202","first-page":"1301","article-title":"Should prednisolone be first-line therapy for acute gout Lancet.","volume":"372","author":"Richette","year":"2008","journal-title":""},{"key":"R39-16-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"R40-16-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":". Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R41-16-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":". Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"R42-16-20210202","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":". The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R43-16-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3349","article-title":"Pegloticase.","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"R44-16-20210202","first-page":"198","article-title":"Refractory gout: what is it and what to do about it Curr Opin Rheumatol.","volume":"20","author":"Fels","year":"2008","journal-title":""},{"key":"R45-16-20210202","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout.","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R46-16-20210202","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":". British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R47-16-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":". National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"R48-16-20210202","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1681\/ASN.2007111256","article-title":". Association of incident gout and mortality in dialysis patients.","volume":"19","author":"Cohen","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R49-16-20210202","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/152692480401400208","article-title":"Treating gout in kidney transplant recipients.","volume":"14","author":"Baroletti","year":"2004","journal-title":"Prog Transplant"},{"key":"R50-16-20210202","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":". Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R51-16-20210202","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":". A pilot study of IL-1 inhibition by anakinra in acute gout.","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R52-16-20210202","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":". Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study.","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R53-16-20210202","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":". Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R54-16-20210202","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":". The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R55-16-20210202","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0091270009351882","article-title":". Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).","volume":"50","author":"Radin","year":"2010","journal-title":"J Clin Pharmacol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201411000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T12:30:29Z","timestamp":1643373029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201411000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318250f83d","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}